Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Ana M,Gonzalez-Angulo

第一单位： Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Ana M,Gonzalez-Angulo ^[1] ; Xiudong,Lei ^[2] ; Richardo H,Alvarez ^[3] ; Majorie C,Green ^[4] ; James L,Murray ^[3] ; Vicente,Valero ^[3] ; Kimberly B,Koenig ^[3] ; Nuhad K,Ibrahim ^[3] ; Jennifer K,Litton ^[3] ; Lakshmy,Nair ^[3] ; Savitri,Krishnamurthy ^[5] ; Gabriel N,Hortobagyi ^[3] ; Funda,Meric-Bernstam ^[6]

作者单位： Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[2] Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[3] Genentech, South San Francisco, CA. ^[4] Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[5] Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fmeric@mdanderson.org. ^[6]

关键词 Chemoresistance Circulating tumor cells Ixabepilone Neoadjuvant systemic therapy Residual disease